CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
gemcitabine +2 moredrug
Likely dose
gemcitabine 1000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00456599
NCT00456599Phase 2Completed
CompareCT.gov

A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

University of Michigan Rogel Cancer Center·interventional·Posted Apr 5, 2007·Updated Dec 3, 2015

In Brief

A Phase 2 clinical trial evaluating gemcitabine, oxaliplatin, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 71 participants across 4 sites in 2 countries.

Detailed Summary

This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesCanada, United States
CollaboratorsSanofi, Johns Hopkins University, Princess Margaret Hospital, Canada, Ohio State University

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 5, 2007
Enrollment StartApr 1, 2007
Primary CompletionMay 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 19.2 years ago

Interventions

gemcitabinedrug

Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.

oxaliplatindrug

Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.

Radiationprocedure

The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.